Skip to main content
Two patients, same diagnosis, same standard biomarkers — different spatial biology and different outcomes. Bioptimus models discover multimodal signatures that separate responders from non-responders, even from the small cohorts typical of early-phase trials.

​
What it enables

  • Build response-predictive signatures from limited early-phase data
  • Support patient enrichment strategies before late-stage commitment
  • Inform trial design with biology the standard biomarker panel misses

​
How it works

1

Embed trial cohorts

Extract features with H-Optimus or M-Optimus.
2

Learn a response signature

Train downstream models that distinguish responders from non-responders.
3

Apply to enrichment & design

Use the signature to inform enrollment and trial design decisions.